MedTrace Logo

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

NCT05273047 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 458

Last updated 2023-09-29

No results posted yet for this study

Summary

The purpose of the IFCT2102 Lung KG12Ci study is to closely monitor cohort ATU applications in order to collect retrospectively, as soon as possible after inclusion and under real-life conditions, the efficacy data on sotorasib (AMG 510) as well as the demographic and molecular characteristics of patients.

Conditions

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Céline Mascaux · Strasbourg - CHU

  • Florian Guisier · Rouen - CHU

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-08-30
Completion
2024-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05273047 on ClinicalTrials.gov